Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, September 15 2020 - 11:00
Standigm Partners with Excelra for GOSTAR to Enhance its AI-driven Drug Discovery Process
HYDERABAD, India and SEOUL, South Korea, Sept. 15, 2020 /PRNewswire-AsiaNet/--

    Excelra [], a global data science and data 
analytics company, today announced its collaboration with Standigm Inc., a 
company using artificial intelligence (AI) technology for drug discovery and 

    Under the agreement, Excelra will provide its small molecule medicinal 
chemistry intelligence platform GOSTAR 
[] to Standigm Inc. GOSTAR provides 
comprehensive information encompassing over 8 million compounds, manually 
curated from 3 million patents and 200,000 journal articles. The database 
contains over 28 million SAR associated data points. The well-structured 
relational database can be utilised for diverse applications across different 
stages of the drug discovery and development lifecycle and aids in target 
validation, hit Identification, early lead Identification and optimization.  

Hanjo Kim, Platform Team Leader, Standigm Inc., said: "For an AI-based drug 
discovery company, high quality SAR data is of great importance. Our platform 
technologies, Standigm BEST(TM), Standigm ASK(TM), and Standigm Insight(TM) 
integrate lots of data to generate innovative ideas including finding novel 
targets, developing predictive models, and designing novel lead series 
compounds. I expect GOSTAR can help this process."

    Raveendra Dayam, Director Chemistry Services, Excelra said: "GOSTAR is the 
largest source for experimentally determined interactions of millions of small 
molecules with most of the potential drug targets. The platform provides a 
comprehensive overview of millions of compounds, linking chemical structure to 
biological, pharmacological and therapeutic activities.  These datasets are 
core to the AI/ML driven drug discovery programs that support rapid discovery 
of novel drug candidates. 

About Standigm: 

    Standigm Inc. is an Artificial Intelligence (AI)-driven drug discovery 
company. Applying its own innovative AI to the real world, Standigm Inc. 
eliminates uncertainty in the drug discovery process and develops therapeutic 
candidates that are primed for success. Pursuing a full-stack, AI-driven 
industrializing drug discovery, Standigm Inc. has achieved the automation of 
molecular design workflow (Dark MolFactory(TM)) and the automation effort has 
been expanding to the whole drug discovery process based on Standigm AI 
platforms, including Standigm ASK(TM) (Target discovery), Standigm BEST(TM) 
(Lead selection), and Standigm Insight(TM) (Drug repurposing). Visit:


    About Excelra:

    Excelra's data science and data analytics solutions empower innovation in 
life sciences. The Excelra Edge comes from a seamless amalgamation of 
proprietary data assets, domain expertise and data science, to accelerate drug 
discovery and development.
    Media Contact: 
    Dorothy Paul
    Director Marketing 

    SOURCE: Excelra Knowledge Solutions Pvt Ltd